PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight
DelveInsight's PLK-1 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging ...
Genentech buys Regor’s CDK inhibitors in $850m deal
Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...
emjreviews.com14h
Genentech acquires Regor’s next-gen CDK inhibitor portfolio
Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...
Food Allergy Research & Education14h
FARE Announces Annual Food Allergy Summit, in Washington DC, October 18-20
Join over 14,000 individuals and families managing food allergies who are sharing their food allergy stories and making a ...
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the ...
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipelineHighlights InstaDeep’s new near exascale supercomputer, Kyber, with the aim of enabling ...